Hyperbilirubinemia is one of the most common neonatal transitional syndromes occurring in 60% to 70% of term infants and virtually all premature infants. 1 Although neonatal jaundice refers to the accumulation of the yellow-orange pigment, bilirubin, in the skin and sclerae of the newborn, some degree of hyperbilirubinemia invariably occurs in the human newborn after birth. The syndrome of neonatal jaundice can be best understood by analogy to a temporarily and partially clogged sink ( Figure 1 ). In this example, the spigot represents the processes of bilirubin production and the drain represents the processes of bilirubin elimination. When the rate at which bilirubin is produced exceeds (spigot ''on'') the rate at which bilirubin can be eliminated (drain ''clogged''), the level of bilirubin in the circulation and body (sink) increases as a result. Therefore, the relative imbalance of these processes determines the pattern and degree of neonatal hyperbilirubinemia, which vary for a variety of reasons and represent the known risk factors (Table 1) .
During the neonatal period, a rapid transition from the intrauterine to the extrauterine pattern of heme catabolism and bilirubin physiology occurs. There is an increase in the production of bilirubin mainly because of a shortened red blood cell lifespan (70 vs 90 days in the neonate) combined with an increased red blood cell mass. Thus, the load of bilirubin faced by the newborn infant is increased two to three times higher on a bodyweight basis as compared to that of an adult.
2 Therefore, the spigot is indeed ''turned on.'' With prematurity, infants have even higher rates of bilirubin production because of a shorter red cell lifespan compared to fullterm newborns. Hepatic uptake and conjugation of bilirubin are also increased after birth. During birth, there is an abrupt interruption of the net flux of unconjugated bilirubin across the placenta from the fetus to the mother, leading to further increases in the circulating bilirubin. In addition, the small amount of bilirubin that is conjugated by the fetus and excreted into bile is deconjugated in the small intestine by -glucuronidase and recirculated for placental transfer. Some bilirubin do, however, accumulate in the gut, contributing to the content of meconium. The persistence of this fetal pattern, which may be prolonged in association with breastfeeding, further contributes to hyperbilirubinemia of the newborn. 3, 4 The influence of breastfeeding on the normal transitional pattern of hyperbilirubinemia should be considered the physiologic circumstance, and formula feeding represents an iatrogenic perturbation of the normal influences of human milk on the enterohepatic circulation of bilirubin.
Eighty to ninety percent of bilirubin is derived from the breakdown of hemoglobin from senescent or hemolyzed red blood cells. The proportion of bilirubin arising from hemoglobin varies with the pathologic condition, and may increase greatly in the circumstance of hemolysis or ineffective erythropoiesis. A smaller proportion of total bilirubin formation comes from the degradation of the heme from other heme-containing proteins, such as myoglobin, cytochromes, guanylyl cyclase, nitric oxide synthase, and others. The first step in the degradation of heme is a microsomal step facilitated by heme oxygenase (HO) and with obligate requirements for NADPH donated through the cytochrome c P450 system and molecular oxygen (Figure 2 ). The catalytic event is actually a series of oxidative and reductive reactions, ultimately breaking the IXmethene bridge, opening up the macrocycle, and yielding equimolar amounts of carbon monoxide (CO), biliverdin, and iron. The second step is a cytosolic step catalyzed by biliverdin reductase also with an obligate requirement for NADPH, yielding bilirubin from biliverdin. Thus, bilirubin and CO are produced in equimolar amounts, and because it is the first step in the process that is ratelimiting, CO production can serve as a surrogate for total bilirubin formation, reflecting an event which occurs nearly ubiquitously throughout the body. Only enucleated mature red cells have been found to lack HO. 5 Detailed reviews of HO and CO biology have been reported previously. 6 -9 For the purposes of this discussion, CO produced through the HO reaction leads directly to an increase in CO bound to circulating hemoglobin, creating carboxyhemoglobin (COHb), and leading to the continuous excretion of CO in breath. The detection of CO in breath as a pulmonary excretion rate of CO (VeCO) or an end-tidal concentration of CO corrected for the ambient CO (ETCOc) can serve as an index of total bilirubin formation. 10 -13 The COHb level can also be used as such an index and there is a predictable relationship among the COHb level, ETCOc, and VeCO 
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under approximate steady state conditions. 14 -19 The relationship between the degradation of heme from the hemoglobin of hemolyzing red cells and CO in breath has been validated in an animal model of the hemolytic condition, demonstrating a molar accountability for degraded heme as CO in breath (Figure 3) . Thus, detection of CO is a valid and extremely sensitive index of hemolysis or any other condition contributing to an increased degradation of heme and bilirubin production.
Although the pattern of neonatal hyperbilirubinemia is not determined completely by the rate of bilirubin production, increased bilirubin production is the circumstance underlying all types of neonatal jaundice. Increased production of the pigment is further increased in premature infants and those infants with bruising or hematoma formation, infants of mothers with glucose intolerance during pregnancy, and infants with all types of hemolysis. 20, 21 There are a variety of reasons why bilirubin production may also be increased in infants with infections including, but not limited, to hemolysis. Even in cholestatic states, bilirubin production is increased because of secondary alterations in the red cell membrane leading to hemolytic anemia. 22 Increased production of bilirubin has also been documented in certain racial groups (e.g., Asians), but it is not clear whether this relates to genetic differences in transitional heme catabolism or environmental factors. 23 The actual pattern of hyperbilirubinemia after birth is influenced importantly by the newborn's capacity to eliminate the pigment. Rare deficiencies (autosomal recessive and/or dominant in nature) in bilirubin uridine diphosphate glucuronosyltransferase (UGT), the enzyme required for bilirubin conjugation, represent examples of 
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Newborn Jaundice incapacities in bilirubin conjugation, which exacerbate neonatal hyperbilirubinemia. A more common genetic predisposition to deficient hepatic uptake of bilirubin and mildly decreased UGT activity in which there are additional thymine-adenine (TA) repeats in the promoter region of the UGT gene has now been described. 24 There are racial variations in the numbers of TA repeats and a correlation with UGT activity, suggesting that these polymorphisms contribute to variations in bilirubin metabolism among the normal population. 24 There is at least one other mutation in the UGT gene that has been identified in Asians, the Gly71Arg (G71R) mutation, which accounts for the increased propensity of some Asian infants (20%) for severe neonatal hyperbilirubinemia. 25 How neonatal jaundice is classified, as either a problem with excessive production of the pigment or impaired capacity to eliminate the pigment, depends upon the net effect of the productionelimination dynamic that is encountered clinically, and there are a variety of diagnoses which tip the balance in one direction or other. The point to be made is that neonatal jaundice is a complex syndrome with varying presentations caused by increased bilirubin production, decreased bilirubin elimination, or a combination of these perturbations.
The importance of increased bilirubin production in some circumstances cannot be denied. Although perhaps representing a unique condition with its own risk profile, the association of increased bilirubin production and glucose-6-phosphate dehydrogenase (G6PD) deficiency-related hemolysis with the risk for kernicterus or death or the failure to respond to phototherapy, thus necessitating exchange transfusion, has been reported. Also, in the presence of hemolysis, the relationship between bilirubin production and hyperbilirubinemia is direct and the former can account for much of the variability (Figure 4) . The converse point can also be made that, in the absence of hemolysis or some other cause of increased bilirubin production, the relationship between bilirubin production and hyperbilirubinemia is less than predictable and more dependent upon the capacity to eliminate the pigment. 21 Nonetheless, the need to identify infants with hemolysis is paramount. In addition, other causes of increased bilirubin production may represent increased risk for injury because of the propensity for higher serum total bilirubin levels and longer duration of exposure to such levels. Information about increased bilirubin production in combination with an hour-specific bilirubin level may allow the practitioner to identify infants with hemolysis as well as those who are not able to eliminate the pigment effectively or may be at higher risk for jaundice requiring therapeutic intervention. 21 For example, an infant with an elevated bilirubin production rate and a normal hour-specific bilirubin is capable of eliminating the pigment efficiently. If the underlying cause of the increased bilirubin production were hemolysis, then anemia would possibly be a late complication, of which the clinician might not be aware in the absence of jaundice. An infant with a high bilirubin production rate and an elevated hour-specific bilirubin is unable to cope with the increased bilirubin load and more likely will develop a high serum total bilirubin level for a longer duration of time. Other pathologic circumstances that are important to diagnose can also be identified with this two-pronged approach. A normal bilirubin production rate in an individual with a high hour-specific bilirubin may have a limited conjugating ability consistent with Gilbert's disease 24,26 -28 or some other mutation (like the G71R mutation in Asians), 25 contributing to a relative deficiency in conjugation and impaired elimination of the pigment. Such an approach would contribute rationality to decision making towards the prevention of hyperbilirubinemia and identification of potentially pathologic and dangerous circumstances in jaundiced infants prior to discharge from the hospital.
Another important point is that even having a diagnosis may not identify the cause of jaundice in a particular case. For example, knowledge that an infant is G6PD-deficient is not sufficient for determining whether the infant will have difficulties with conjugation of bilirubin because of coincident Gilbert's disease or hemolysis, which may result from an environmental exposure to an oxidant. A common misconception is the assumption that blood type incompatibility and positive Coombs' test equate with hemolysis. A positive Coombs' test only indicates the presence of antibody on the surface of the red cell and should not be equated with red cell breakdown. In fact, a positive Coombs' test can be associated with normal bilirubin production, or a weakly positive Coombs' or negative Coombs' test can be associated with an increased hemolytic rate. In summary, understanding neonatal jaundice requires an understanding of the dynamic imbalance between increased bilirubin production and decreased capacity to eliminate the pigment. The various diagnoses and risk factors serve only to suggest the likelihood of such an imbalance, which may need to be assessed directly through the estimation of the roles of both production and elimination rates of bilirubin. Specifically, an estimate of CO production as an index of total bilirubin formation (e.g., ETCOc), combined with an hour-specific bilirubin, as an index of bilirubin elimination will provide a window to this bilirubin productionelimination dynamic and can direct more targeted therapies to prevent or treat severe hyperbilirubinemia.
